MedTrace Logo

Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome?

NCT07774884 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2026-08-19

No results posted yet for this study

Summary

Masticatory myofascial pain syndrome (MMPS) is a common and debilitating orofacial pain condition characterized by localized or referred pain originating from trigger points in the masticatory muscles. The condition significantly impairs quality of life, affecting mastication, speech, and psychosocial well-being. The masseter and temporalis muscles are the most frequently targeted muscles in conventional botulinum toxin type A (BoNT-A) therapy for MMPS; however, the medial pterygoid muscle, a primary jaw-closing muscle, is often overlooked due to its deep anatomical location and the technical challenges associated with its injection.

Conditions

  • Masticatory Myofascial Pain Syndrome

Interventions

PROCEDURE

conventional BoNT-A treatment

botulinum toxin type A injection into the bilateral masseter and temporalis muscles

PROCEDURE

Placebo

placebo/sham injection protocol

PROCEDURE

conventional treatment plus medial pterygoid injection

masseter and temporalis injections as Group A, in addition to targeted injection of the clinically involved medial pterygoid muscle

Sponsors & Collaborators

  • Fayoum University

    lead OTHER

Principal Investigators

  • Alshaimaa Mohamed · Fayoum University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-03-01
Completion
2027-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07774884 on ClinicalTrials.gov